| 8.83 -0.16 (-1.78%) | 11-29 11:16 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.25 | 1-year : | 14.31 |
| Resists | First : | 10.48 | Second : | 12.25 |
| Pivot price | 8.85  |
|||
| Supports | First : | 8.01 | Second : | 6.48 |
| MAs | MA(5) : | 8.96 |
MA(20) : | 8.71  |
| MA(100) : | 6.49 |
MA(250) : | 7.14 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 46.9 |
D(3) : | 47.7 |
| RSI | RSI(14): 55.8 |
|||
| 52-week | High : | 12.32 | Low : | 3.93 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ALXO ] has closed below upper band by 47.9%. Bollinger Bands are 18.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.19 - 9.23 | 9.23 - 9.26 |
| Low: | 8.48 - 8.52 | 8.52 - 8.56 |
| Close: | 8.93 - 8.99 | 8.99 - 9.05 |
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
Wed, 22 Nov 2023
Noteworthy Wednesday Option Activity: OMI, ALXO, SPOT - Nasdaq
Mon, 13 Nov 2023
ALX Oncology Holdings Inc (ALXO) Reports Q3 2023 Financial Results and Corporate Developments - Yahoo Finance
Wed, 01 Nov 2023
ALX Oncology Announces November Investor Conference Participation - Yahoo Finance
Fri, 06 Oct 2023
The Zacks Analyst Blog Highlights Novavax, ALX Oncology ... - Yahoo Finance
Thu, 05 Oct 2023
Alx Oncology Holdings (ALXO) Price Target Increased by 13.11% to ... - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 21 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 99 (%) |
| Shares Short | 3,820 (K) |
| Shares Short P.Month | 2,670 (K) |
| EPS | -3.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.09 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36 % |
| Return on Equity (ttm) | -64.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -111 (M) |
| Levered Free Cash Flow | -65 (M) |
| PE Ratio | -2.5 |
| PEG Ratio | 0 |
| Price to Book value | 2.17 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|